The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS

被引:202
作者
O'Brien, SJ [1 ]
Moore, JP
机构
[1] NCI, Lab Genom Divers, Frederick, MD 21702 USA
[2] Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY USA
关键词
D O I
10.1034/j.1600-065X.2000.17710.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pivotal discovery that two chemokine receptors, CCR5 and CXCR4, serve along with the T-cell receptor-interacting CD4 molecule as the principal co-receptors for HIV-1 entry stimulated a search for common genetic polymorphism in their genes which might affect the course of AIDS. Four mutational variants, CCR5-Delta 32, CCR5-P1, CCR2-64I and SDF1-3'A were discovered to play a regulatory role in HIV-1 infection, in the rate of progression to AIDS or both. Plausible physiological mechanisms to explain the population genetic association by these alleles have been advanced and are discussed critically here. Genetic ablation of AIDS progression by chemokine receptor and Ligand gene variants has catalyzed development of novel therapies targeting the virus-co-receptor interaction. The functional and therapeutic implications of these AIDS restriction genes for disease progression and intervention are explored in this review.
引用
收藏
页码:99 / 111
页数:13
相关论文
共 133 条
  • [1] CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells
    Aliberti, J
    Sousa, CRE
    Schito, M
    Hieny, S
    Wells, T
    Huffnagle, GB
    Sher, A
    [J]. NATURE IMMUNOLOGY, 2000, 1 (01) : 83 - 87
  • [2] CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1
    Alkhatib, G
    Combadiere, C
    Broder, CC
    Feng, Y
    Kennedy, PE
    Murphy, PM
    Berger, EA
    [J]. SCIENCE, 1996, 272 (5270) : 1955 - 1958
  • [3] The extent of genetic variation in the CCR5 gene
    AnsariLari, MA
    Liu, XM
    Metzker, ML
    Rut, AR
    Gibbs, RA
    [J]. NATURE GENETICS, 1997, 16 (03) : 221 - 222
  • [4] CCR2-64I allele and genotype association with delayed AIDS progression in African women
    Anzala, AO
    Ball, TB
    Rostron, T
    O'Brien, SJ
    Plummer, FA
    Rowland-Jones, SL
    [J]. LANCET, 1998, 351 (9116) : 1632 - 1633
  • [5] HIV blocked by chemokine antagonist
    ArenzanaSeisdedos, F
    Virelizier, JL
    Rousset, D
    ClarkLewis, I
    Loetscher, P
    Moser, B
    Baggiolini, M
    [J]. NATURE, 1996, 383 (6599) : 400 - 400
  • [6] Arya SK, 1999, J HUMAN VIROL, V2, P133
  • [7] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
    Baba, M
    Nishimura, O
    Kanzaki, N
    Okamoto, M
    Sawada, H
    Iizawa, Y
    Shiraishi, M
    Aramaki, Y
    Okonogi, K
    Ogawa, Y
    Meguro, K
    Fujino, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703
  • [8] Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1
    Bajetto, A
    Bonavia, R
    Barbero, S
    Piccioli, P
    Costa, A
    Florio, T
    Schettini, G
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 73 (06) : 2348 - 2357
  • [9] Homozygous Delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient
    Balotta, C
    Bagnarelli, P
    Violin, M
    Ridolfo, AL
    Zhou, D
    Berlusconi, A
    Corvasce, S
    Corbellino, M
    Clementi, M
    Clerici, M
    Moroni, M
    Galli, M
    [J]. AIDS, 1997, 11 (10) : F67 - F71
  • [10] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
    Benkirane, M
    Jin, DY
    Chun, RF
    Koup, RA
    Jeang, KT
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606